Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen (ARTISTRY-1) (ARTISTRY-1)

4. november 2026 oppdatert av: Gilead Sciences

En operasjonelt sømløs fase 2/3 randomisert, åpen, multisenter, aktivt kontrollert studie for å evaluere sikkerheten og effekten av Bictegravir/Lenacapavir versus stabil baseline-regime hos virologisk undertrykte personer med HIV-1 på stabile komplekse behandlingsregimer

The goal of this clinical study is to learn more about the effects of switching to the study drugs, bictegravir (BIC) plus lenacapavir (LEN), versus current therapy (Phase 2) and BIC/LEN fixed-dose combination (FDC) versus current therapy (Phase 3) in people living with HIV (PWH).

Studieoversikt

Studietype

Intervensjonell

Registrering (Faktiske)

689

Fase

  • Fase 2
  • Fase 3

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

      • Buenos Aires, Argentina, 1202
        • Fundación Huésped
      • Buenos Aires, Argentina, 1072
        • Hospital General de Agudos J.M Ramon Mejia
      • Buenos Aires, Argentina, 1425
        • Helios Salud
    • New South Wales
      • Darlinghurst, New South Wales, Australia, 2010
        • St.Vincent's Hospital Sydney
      • Darlinghurst, New South Wales, Australia, 2011
        • Taylor Square Private Clinic
      • Sydney, New South Wales, Australia, 2010
        • Holdsworth House Medical Practice
    • Victoria
      • Melbourne, Victoria, Australia, 3004
        • Alfred Health
      • Decarie Montreal, Canada, H4A 3J1
        • Chronic Viral Illness Service / McGill University Health Centre (MUHC)
      • Montreal, Canada, H2L 0B1
        • Clinique Medicale du Quartier Latin
      • Ottawa, Canada, K1H 8L6
        • The Ottawa Hospital - General Campus
      • Regina, Canada, S4P 0W5
        • ID Clinic
      • Toronto, Canada, M5G 1K2
        • Maple Leaf Research
      • Vancouver, Canada, V6Z 2T1
        • Spectrum Health
      • Santo Domingo, Den dominikanske republikk
        • Instituto Dominicano de Estudio Virologicos - IDEV
    • California
      • Berkeley, California, Forente stater, 48072
        • Be Well Medical Center
      • Beverly Hills, California, Forente stater, 90211
        • Pacific Oaks Medical Group
      • Los Angeles, California, Forente stater, 90036
        • Ruane Clinical Research Group, Inc
      • Oakland, California, Forente stater, 94609
        • Alta Bates Summit Medical Center, Summit Campus, East Bay Advanced Care
      • Palm Springs, California, Forente stater, 92262
        • Bios Clinical Research
      • San Diego, California, Forente stater, 92103
        • University of California San Diego (UCSD)
      • Torrance, California, Forente stater, 90502
        • Lundquist Institute for Biomedical Innovation at Harbor - UCLA Medical Center
      • West Hollywood, California, Forente stater, 90046
        • The Men's Health Foundation
    • Colorado
      • Denver, Colorado, Forente stater, 80204
        • Denver Health Medical Center
    • Connecticut
      • New Haven, Connecticut, Forente stater, 06510
        • Yale University; School of Medicine; AIDS Program
    • Florida
      • DeLand, Florida, Forente stater, 32720
        • Midland Florida Clinical Research Center, LLC
      • Fort Lauderdale, Florida, Forente stater, 33316
        • Gary Richmond, MD, PA, Inc.
      • Fort Lauderdale, Florida, Forente stater, 33308
        • Therafirst Medical Centers
      • Ft. Pierce, Florida, Forente stater, 34982
        • Midway Immunology & Research Center, LLC
      • Miami, Florida, Forente stater, 33136
        • Schiff Center for liver Diseases/University of Miami
      • Miami Lakes, Florida, Forente stater, 33016
        • Floridian Clinical Research
      • Orlando, Florida, Forente stater, 32803
        • Orlando Immunology Center
      • Orlando, Florida, Forente stater, 32803
        • Therapeutic Concepts, PA
      • West Palm Beach, Florida, Forente stater, 33407
        • Triple O Research Institute PA
    • Georgia
      • Atlanta, Georgia, Forente stater, 30309
        • Atlanta ID Group
      • Macon, Georgia, Forente stater, 31201
        • Mercer University School of Medicine
    • Illinois
      • Chicago, Illinois, Forente stater, 60613
        • Howard Brown Health Center
    • Missouri
      • Kansas City, Missouri, Forente stater, 64111
        • Kansas City Care Clinic
      • St Louis, Missouri, Forente stater, 63139
        • Southampton Healthcare, Inc.
    • New Jersey
      • Newark, New Jersey, Forente stater, 07102
        • Saint Michael's Medical Center
    • New Mexico
      • Santa Fe, New Mexico, Forente stater, 87505
        • AXCES Research Group
    • New York
      • Flushing, New York, Forente stater, 11355
        • New York Presbyterian Hospital
      • New York, New York, Forente stater, 10001
        • Ricky K. Hsu, MD, PC
    • North Carolina
      • Chapel Hill, North Carolina, Forente stater, 27514
        • University of North Carolina - Chapel Hill
      • Greenville, North Carolina, Forente stater, 27858
        • East Carolina University
    • Pennsylvania
      • Philadelphia, Pennsylvania, Forente stater, 19107
        • Philadelphia FIGHT
    • South Carolina
      • Charleston, South Carolina, Forente stater, 29425
        • Medical University of South Carolina (MUSC) Research NEXUS
    • Texas
      • Austin, Texas, Forente stater, 78705
        • Central Texas Clinical Research
      • Bellaire, Texas, Forente stater, 77401
        • St. Hope Foundation
      • Dallas, Texas, Forente stater, 75246
        • North Texas Infectious Diseases Consultants
      • Dallas, Texas, Forente stater, 75208
        • AIDS Arms, Inc., DBA Prism Health North Texas
      • Fort Worth, Texas, Forente stater, 76104
        • Texas Centers for Infectious Disease Associates
      • Houston, Texas, Forente stater, 77098
        • Gordon E. Crofoot MD PA
      • Longview, Texas, Forente stater, 75605
        • Diagnostic Clinic of Longview - Center for Clinical Research
    • Washington
      • Seattle, Washington, Forente stater, 98104
        • Peter Shalit, MD
      • Nice, Frankrike, 6202
        • CHU Nice-Hôpital l'Archet
      • Paris, Frankrike, 75010
        • Hospital Saint Louis
      • Paris, Frankrike, 75018
        • Groupe Hospitalier Bichat Claude Bernard
      • Paris, Frankrike, 75651
        • Höpital de la Pitié Salpêtrière
      • Milan, Italia, 20157
        • ASST Fatebenefratelli Sacco
      • Milan, Italia, 20127
        • IRCCS Ospedale San Raffaele
      • Modena, Italia, 40124
        • Azienda Ospedaliero-Universitaria di Modena
      • Roma, Italia, 00149
        • Istituto Nazionale Malattie Infettive "Lazzaro Spallanzani" IRCCS
      • Torino, Italia, 10149
        • ASL Città di Torino
      • Nagoya, Japan
        • National Hospital Organization Nagoya Medical Center
      • Osaka, Japan, 540-0006
        • National Hospital Organization Osaka National Hospital
      • Tokyo, Japan, 162-0052
        • Center Hospital of the National Center for Global Health and Medicine
    • PR
      • San Juan, PR, Puerto Rico, 00909
        • Hope Clinical Research
      • San Juan, PR, Puerto Rico, 00935
        • Proyecto ACTU
      • Barcelona, Spania, 08036
        • Hospital Clinic Provincial de Barcelona
      • Madrid, Spania, 28040
        • Hospital Clinico San Carlos
      • Madrid, Spania, 28046
        • Hospital Universitario La Paz
      • Madrid, Spania, 28034
        • Hospital Ramon y Cajal, Madrid
      • Seville, Spania, 4103
        • Hospital Universitario Virgen del Rocio
      • Birmingham, Storbritannia, B9 5SS
        • Department of HIV & Sexual Medicine
      • Brighton, Storbritannia, BN2 3EW
        • Brighton and Sussex University Hospitals NHS Trust
      • London, Storbritannia, E1 1BB.
        • Barts Health NHS Trust
      • London, Storbritannia, SE5 9RS
        • HIV medicine and infectious diseases
      • London, Storbritannia, SW109NH
        • St.Stephen's AIDS Trust, Clinical Trials Unit, 1st Floor, St.Stephen's Centre
      • Daegu, Sør -Korea, 41944
        • Kyungpook National University Hospital
      • Daejeon, Sør -Korea, 35015
        • Chungnam National University Hospital
      • Seoul, Sør -Korea, 06591
        • The Catholic University of Korea Seoul St. Mary's Hospital
      • Seoul, Sør -Korea, 03722
        • Yonsei University Severance Hospital
      • Cape Town, Sør-Afrika, 7925
        • Desmond Tutu Health Foundation Clinical Trials Unit
      • Ga-Rankuwa, Sør-Afrika, 208
        • Sefako Makgatho Health Sciences University
      • Johannesburg, Sør-Afrika, 2193
        • Ezintsha
      • Kaohsiung City, Taiwan, 80756
        • Kaohsiung Medical University Chung-Ho Memorial Hospital
      • Kaohsiung City, Taiwan, 81362
        • Kaohsiung Medical University Chung-Ho Memorial Hospital
      • New Taipei City, Taiwan, 22060
        • Far Eastern Memorial Hospital
      • Taoyuan City, Taiwan, 33004
        • Taoyuan General Hospital
      • Berlin, Tyskland, 10439
        • zibp Zentrum für Infektiologie Berlin Prenzlauer Berg GmbH
      • Bonn, Tyskland, 53127
        • Universitatsklinikum Bonn
      • Frankfurt, Tyskland, 60596
        • Infektio Research GmbH & Co.KG
      • Hamburg, Tyskland, 20146
        • ICH Study Center GmbH & Co. KG
      • München, Tyskland
        • MVZ München am Goetheplatz

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Key Inclusion Criteria:

  • If plasma HIV-1 RNA measurements in the 6 months prior to screening are available, all levels must be < 50 copies/mL.

  • At least one documented plasma HIV-1 RNA level measured between 6 and 12 months (± 2 months) prior to screening. This and any other HIV-1 RNA measurements documented in this period must be < 50 copies/mL

  • Plasma HIV-1 RNA levels < 50 copies/mL at screening.

  • Currently receiving a complex antiretroviral (ARV) regimen due to previous viral resistance, or intolerance, or contraindication to existing single-tablet regimens (STR), and on this regimen for at least 6 months prior to the screening visit. The criteria to define a complex regimen in this study are as follows:

    • A regimen containing a boosted protease inhibitor or a nonnucleos(t)ide reverse transcriptase inhibitor (NRTI) plus at least 1 other third agent (ie, an agent from a class other than NRTIs) (eg, bictegravir/emtricitabine/tenofovir alafenamide (coformulated; Biktarvy®)(BVY) + darunavir/cobicistat, BVY + etravirine), or
    • A regimen of ≥ 2 pills/day, or a regimen requiring dosing more than once daily, or
    • A regimen containing parenteral agent(s) (excluding a complete long-acting injectable regimen, such as intramuscular cabotegravir plus rilpivirine) as well as oral agents.
  • No documented or suspected resistance to bictegravir (BIC).

  • Estimated glomerular filtration rate ≥ 15 mL/min according to the Cockcroft-Gault formula for creatinine clearance (CLcr) who are not on renal replacement therapy.

Key Exclusion Criteria:

  • Prior use of, or exposure to, lenacapavir (LEN)
  • Active tuberculosis infection
  • Chronic hepatitis B virus (HBV) infection

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Phase 2: Treatment Group 1: BIC 75 mg + LEN 25 mg

Participants will switch from their Stable Baseline Regimen (SBR) to a regimen of BIC 75 mg + LEN 25 mg, tablets administered orally once daily for up to 24 weeks. Participants will receive a 2-day pharmacokinetic (PK) oral loading dose of LEN 600 mg, on Days 1 and 2, in addition to the daily doses of BIC 75 mg + LEN 25 mg starting on Day 1.

Participants who discontinue early or complete the Randomized Phase (RP) will have an option to continue in Extension Period (EP)

Tablets administered orally without regard to food

Andre navn:
  • GS-6207

Tablets administered orally without regard to food

Andre navn:
  • GS-9883
Eksperimentell: Phase 2: Treatment Group 2: BIC 75 mg + LEN 50 mg

Participants will switch from their SBR to a regimen of BIC 75 mg + LEN 50 mg, tablets administered orally once daily for up to 24 weeks. Participants will receive a 2-day PK oral loading dose of LEN 600 mg, on Days 1 and 2, in addition to the daily doses of BIC 75 mg + LEN 50 mg starting on Day 1.

Participants who discontinue early or complete the RP will have an option to continue in EP.

Tablets administered orally without regard to food

Andre navn:
  • GS-6207

Tablets administered orally without regard to food

Andre navn:
  • GS-9883
Aktiv komparator: Phase 2: Treatment Group 3: SBR

Participants will continue with their SBR for up to 24 weeks.

Participants who discontinue early or complete the RP will have an option to continue in EP.

SBR will include a combination of antiretroviral (ARV) regimen. ARV regimen may include the following, except for participants taking a single tablet regimen or taking a complete parenteral regimen (Cabenuva).

  • Nucleos(t)ide Reverse Transcriptase Inhibitors:

    • Abacavir
    • Emtricitabine
    • Lamivudine
    • Tenofovir alafenamide
    • Tenofovir disoproxil fumarate
    • Zidovudine
  • Non-Nucleosite Reverse Transcriptase Inhibitors:

    • Delavirdine
    • Efavirenz
    • Nevirapine
    • Rilpivirine
    • Doravirine
  • Integrase Inhibitors:

    • Bictegravir
    • Cabotegravir
    • Dolutegravir
    • Elvitegravir
    • Raltegravir
  • Protease Inhibitors:

    • Atazanavir
    • Darunavir
    • Fosamprenavir
    • Indinavir
    • Lopinavir
    • Nelfinavir
    • Saquinavir
    • Tipranavir
  • Chemokine Co-receptor 5 (CCR5) Antagonist:

    • Maraviroc
  • Fusion Inhibitors:

    • Enfuvirtide
  • gp120 Attachment Inhibitor:

    • Fostemsavir
  • Anti-CD4 Monoclonal Antibodies:

    • Ibalizumab-uiyk
Eksperimentell: Phase 3: Treatment Group 1: BIC/LEN 75 mg/50 mg FDC

Participants will switch from their SBR to a regimen of BIC/LEN 75mg/50mg FDC, administered orally once daily for up to 48 weeks. Participants will receive a 2-day PK oral loading dose of LEN 600 mg, on Days 1 and 2, in addition to the daily doses of BIC/LEN 75 mg/50 mg FDC starting on Day 1.

Participants who discontinue early or complete the RP will have an option to continue in EP.

Tablets administered orally without regard to food

Andre navn:
  • Bixlenvo™
Aktiv komparator: Phase 3: Treatment Group 2: SBR

Participants will continue with their SBR for up to 48 weeks.

Participants who will discontinue early or complete the RP had an option to continue in EP.

SBR will include a combination of antiretroviral (ARV) regimen. ARV regimen may include the following, except for participants taking a single tablet regimen or taking a complete parenteral regimen (Cabenuva).

  • Nucleos(t)ide Reverse Transcriptase Inhibitors:

    • Abacavir
    • Emtricitabine
    • Lamivudine
    • Tenofovir alafenamide
    • Tenofovir disoproxil fumarate
    • Zidovudine
  • Non-Nucleosite Reverse Transcriptase Inhibitors:

    • Delavirdine
    • Efavirenz
    • Nevirapine
    • Rilpivirine
    • Doravirine
  • Integrase Inhibitors:

    • Bictegravir
    • Cabotegravir
    • Dolutegravir
    • Elvitegravir
    • Raltegravir
  • Protease Inhibitors:

    • Atazanavir
    • Darunavir
    • Fosamprenavir
    • Indinavir
    • Lopinavir
    • Nelfinavir
    • Saquinavir
    • Tipranavir
  • Chemokine Co-receptor 5 (CCR5) Antagonist:

    • Maraviroc
  • Fusion Inhibitors:

    • Enfuvirtide
  • gp120 Attachment Inhibitor:

    • Fostemsavir
  • Anti-CD4 Monoclonal Antibodies:

    • Ibalizumab-uiyk
Eksperimentell: Phase 2/Phase 3:BIC/LEN 75/50 mg FDC

At the end of randomized treatment, participants in Phase 2 and Phase 3 treatment groups who discontinue early or complete the RP will be given an option to enter in EP and will receive BIC/LEN 75/50 mg FDC until the drug is available in market or Gilead elects to withdraw the study. Participants in the SBR groups (Phase 2 Treatment Group 3 and Phase 3 Treatment Group 2 will also receive a 2-day PK oral loading dose of LEN 600 mg, on Days 1 and 2 of EP).

Tablets administered orally without regard to food

Andre navn:
  • GS-6207

Tablets administered orally without regard to food

Andre navn:
  • Bixlenvo™

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Phase 2: Percentage of Participants With Human Immunodeficiency Virus-1 Ribonucleic Acid (HIV-1 RNA) ≥ 50 Copies/mL at Week 24 as Determined by the United States Food and Drug Administration (US FDA) Defined Snapshot Algorithm
Tidsramme: Week 24

Participants who had the last available on-treatment HIV-1 RNA≥ 50 copies/mL in the week 24 analysis window, or who did not have on-treatment HIV-1 RNA data in the week 24 analysis window and participants who discontinued study drug prior to or in the week 24 analysis window due to lack of efficacy, or who discontinued study drug prior to or in the week 24 analysis window due to adverse event (AE) or death and have the last available on-treatment HIV-1 RNA≥ 50 copies/mL, or who discontinued study drug prior to or in the week 24 analysis window due to reasons other than AE, death, or lack of efficacy and have the last available on-treatment HIV-1 RNA ≥ 50 copies/mL were included. The Week 24 window for snapshot algorithm was between Days 127 and 210 (inclusively). Percentages were rounded off.

Week 24
Phase 3: Percentages of Participants With HIV-1 RNA ≥ 50 Copies/mL at Week 48 as Determined by the US FDA-defined Snapshot Algorithm
Tidsramme: Week 48

Participants who had the last available on-treatment HIV-1 RNA ≥ 50 copies/mL in the Week 48 analysis window, or who did not have on-treatment HIV-1 RNA data in the Week 48 analysis window and who discontinued study drug prior to or in the Week 48 analysis window due to lack of efficacy, or who discontinued study drug prior to or in the Week 48 analysis window due to AE or death and have the last available on-treatment HIV-1 RNA ≥ 50 copies/mL, or who discontinued study drug prior to or in the Week 48 analysis window due to reasons other than AE, death, or lack of efficacy and have the last available on-treatment HIV-1 RNA ≥ 50 copies/mL were included. The Week 48 window for snapshot algorithm was between Days 295 and 378 (inclusively). Percentages were rounded off.

Week 48

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Phase 2: Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 24 as Determined by the US FDA-defined Snapshot Algorithm
Tidsramme: Week 24

Participants who had the last available on-treatment HIV-1 RNA < 50 copies/mL in the Week 24 analysis window were included. The Week 24 window for snapshot algorithm was between Days 127 and 210 (inclusively). Percentages were rounded off.

Week 24
Phase 2: Change From Baseline in Clusters of Differentiation 4 (CD4) Cell Count at Week 24
Tidsramme: Baseline, Week 24
Baseline, Week 24
Phase 2: Percentage of Participants Experiencing Treatment-Emergent Adverse Events (TEAEs) Through Week 24
Tidsramme: First dose date up to Week 24

An adverse event (AE) was any untoward medical occurrence in a clinical study participant administered a study drug that did not necessarily had a causal relationship with the treatment. TEAEs were defined as any AE that begins on or after the date of first dose of study drug up to the date of last dose of study drug plus 60 days (for BIC+LEN or BIC/LEN FDC) or 30 days (for SBR) or any AE leading to study drug discontinuation. Percentages were rounded off.

First dose date up to Week 24
Phase 2: PK Parameter: Cmax for Bictegravir (BIC) at Steady State
Tidsramme: At Week 16 or 24

Cmax is defined as the maximum observed concentration of drug. Participants chose to participate at either Week 16 or Week 24 visit as the steady state visit.

At Week 16 or 24
Phase 2: PK Parameter: Cmax for Lenacapavir (LEN) at Steady State
Tidsramme: At Week 16 or Week 24

Cmax is defined as the maximum observed concentration of drug. Participants chose to participate at either Week 16 or Week 24 visit as the steady state visit.

At Week 16 or Week 24
Phase 2: PK Parameter: AUCtau of BIC at Steady State
Tidsramme: At Week 16 or 24

AUCtau is defined as the area under the concentration versus time curve over the dosing interval. Participants chose to participate at either Week 16 or Week 24 visit as the steady state visit.

At Week 16 or 24
Phase 2: PK Parameter: AUCtau for LEN at Steady State
Tidsramme: At Week 16 or Week 24

AUCtau is defined as the area under the concentration versus time curve over the dosing interval. Participants chose to participate at either Week 16 or Week 24 visit as the steady state visit.

At Week 16 or Week 24
Phase 2: PK Parameter: Ctrough of BIC at Steady State
Tidsramme: At Week 16 or Week 24

Ctrough is defined as the observed drug concentration at the end of the dosing interval. Participants chose to participate at either Week 16 or Week 24 visit as the steady state visit.

At Week 16 or Week 24
Phase 2: PK Parameter: Ctrough of LEN at Steady State
Tidsramme: At Week 16 or Week 24

Ctrough is defined as the observed drug concentration at the end of the dosing interval. Participants chose to participate at either Week 16 or Week 24 visit as the steady state visit.

At Week 16 or Week 24
Phase 3: Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48 as Determined by the US FDA-defined Snapshot Algorithm
Tidsramme: Week 48

Participants who had the last available on-treatment HIV-1 RNA < 50 copies/mL in the Week 48 analysis window were included. The Week 48 window for snapshot algorithm was between Days 295 and 378 (inclusively).

Week 48
Phase 3: Change From Baseline in CD4 Cell Count at Week 48
Tidsramme: Baseline, Week 48

An AE was any untoward medical occurrence in a clinical study participant administered a study drug that did not necessarily had a causal relationship with the treatment. TEAEs were defined as any AE that begins on or after the date of first dose of study drug up to the date of last dose of study drug plus 60 days (for BIC+LEN or BIC/LEN FDC) or 30 days (for SBR) or any AE leading to study drug discontinuation. Percentages were rounded off.

Baseline, Week 48
Phase 3: Percentage of Participants Experiencing TEAEs Through Week 48
Tidsramme: First dose date up to Week 48

An AE was any untoward medical occurrence in a clinical study participant administered a study drug that did not necessarily had a causal relationship with the treatment. TEAEs were defined as 1 or both of the following: Any AEs leading to premature discontinuation of study drug, or any AEs with an onset date on or after the study drug start date and no later than the last exposure date after permanent discontinuation of the study drug. Percentages were rounded off.

First dose date up to Week 48
Phase 3 Treatment Group 1: (BIC/LEN 75 mg/50 mg FDC): Percentage of Participants With HIV-1 RNA ≥ 50 Copies/mL at Week 96 as Determined by the US FDA-defined Snapshot Algorithm
Tidsramme: Week 96
Week 96
Phase 3 Treatment Group 1: (BIC/LEN 75 mg/50 mg FDC): Percentage of Participants With HIV-1 RNA ≥ 50 Copies/mL at Week 144 as Determined by the US FDA-defined Snapshot Algorithm
Tidsramme: Week 144
Week 144
Phase 3 Treatment Group 1: (BIC/LEN 75 mg/50 mg FDC): Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 96 as Determined by the US FDA-defined Snapshot Algorithm
Tidsramme: Week 96
Week 96
Phase 3 Treatment Group 1: (BIC/LEN 75 mg/50 mg FDC): Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 144 as Determined by the US FDA-defined Snapshot Algorithm
Tidsramme: Week 144
Week 144
Phase 3 Treatment Group 1: (BIC/LEN 75 mg/50 mg FDC): Change From Baseline in CD4 Cell Count at Week 96
Tidsramme: Baseline, Week 96
Baseline, Week 96
Phase 3 Treatment Group 1: (BIC/LEN 75 mg/50 mg FDC): Change From Baseline in CD4 Cell Count at Week 144
Tidsramme: Baseline, Week 144
Baseline, Week 144
Phase 3 Treatment Group 1: (BIC/LEN 75 mg/50 mg FDC): Percentage of Participants Experiencing TEAEs Through Week 96
Tidsramme: Week 96
Week 96
Phase 3 Treatment Group 1: (BIC/LEN 75 mg/50 mg FDC): Percentage of Participants Experiencing TEAEs Through Week 144
Tidsramme: Week 144
Week 144

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

Publikasjoner og nyttige lenker

Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

16. august 2022

Primær fullføring (Faktiske)

29. september 2025

Studiet fullført (Antatt)

1. desember 2029

Datoer for studieregistrering

Først innsendt

5. august 2022

Først innsendt som oppfylte QC-kriteriene

12. august 2022

Først lagt ut (Faktiske)

16. august 2022

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

5. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

4. november 2026

Sist bekreftet

1. november 2026

Mer informasjon

Begreper knyttet til denne studien

Ytterligere relevante MeSH-vilkår

Andre studie-ID-numre

  • GS-US-621-6289
  • 2022-500929-33 (Annen identifikator: European Medicines Agency)
  • DOH-27-052023-8574 (Annen identifikator: South African Clinical Trial Registry)
  • jRCT2051230168 (Annen identifikator: Japan registry)

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Ja

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere